Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|May 14, 2024
A unified Bayesian framework for bias adjustment in multiple comparisons from clinical trialsYu Du, Jianghao Li, Sohini Raha, et al.
Diabetes, Obesity & Metabolism|April 17, 2026
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or OverweightXiaosu Ma, Ying Grace Li, Sohini Raha, et al.
Diabetes Care|January 19, 2022
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND TrialAnita Y M Kwan, Hertzel C Gerstein, Jan Basile, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11Juan P Frias, Enzo Bonora, David A Cox, et al.
Clinical Pharmacology and Therapeutics|July 3, 2026
Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor AgonistBridget L Morse, David E Coutant, Xiaosu Ma, et al.
Cardiovascular Diabetology|March 10, 2023
General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trialEdward Franek, Prem Pais, Jan Basile, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 13, 2021
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11Joanna Van, Juan P Frias, Enzo Bonora, et al.
Diabetes, Obesity & Metabolism|June 23, 2021
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trialJuan P Frias, Enzo Bonora, Luis Nevárez Ruiz, et al.
Scandinavian Cardiovascular Journal : SCJ|February 1, 2023
Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trialGiulia Ferrannini, Juan M Maldonado, Sohini Raha, et al.
Cardiovascular Diabetology|September 26, 2021
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWINDManige Konig, Matthew C Riddle, Helen M Colhoun, et al.
Pageof 2